<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812977</url>
  </required_header>
  <id_info>
    <org_study_id>094/HEC/PICO/18</org_study_id>
    <nct_id>NCT04812977</nct_id>
  </id_info>
  <brief_title>Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion</brief_title>
  <acronym>CRVO</acronym>
  <official_title>Comparison of Intravitreal Bevacizumab and Triamcinolone Acetonide With Intravitreal Bevacizumab Alone in Macular Edema Secondary to Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hayatabad Medical Complex</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hayatabad Medical Complex</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of intravitreal-Bevacizumab and Triamcinolone with&#xD;
      intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with&#xD;
      macular edema secondary to central retinal vein occlusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2018</start_date>
  <completion_date type="Actual">December 10, 2018</completion_date>
  <primary_completion_date type="Actual">December 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>central foveal thickness</measure>
    <time_frame>6 months</time_frame>
    <description>change in central foveal thickness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Central Retinal Vein Occlusion With Macular Edema</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A</intervention_name>
    <description>Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of either gender, age 40-80 years, having macular edema secondary to CRVO,&#xD;
             Best-corrected visual acuity (BCVA) of less than or equal to 0.3 on Log MAR chart&#xD;
             (Snellen equivalent of 6/12), Central foveal thickness CFT greater than or equal to&#xD;
             250 microns on Heidelberg Spectralis Spectral Domain Optical coherence tomography&#xD;
             (SD-OCT) and clinical diagnosis of CRVO.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previously received laser treatment and/or intravitreal injection of any Anti-VEGF&#xD;
             agent, having one eye, diagnosed case of glaucoma, family history of glaucoma, young&#xD;
             patient, and anyone who has received any treatment for CRVO before presenting to us.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hayatabad Medical Complex</name>
      <address>
        <city>Peshawar</city>
        <state>KPK</state>
        <zip>25000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Yoshizawa C, Saito W, Kase M, Ishida S. Clinical Features of Central Retinal Vein Occlusion With Inflammatory Etiology. Asia Pac J Ophthalmol (Phila). 2012 Sep-Oct;1(5):270-6. doi: 10.1097/APO.0b013e318266de04.</citation>
    <PMID>26107597</PMID>
  </reference>
  <reference>
    <citation>Lazić R, Boras I, Vlasić M, Gabrić N, Tomić Z. Anti-VEGF in treatment of central retinal vein occlusion. Coll Antropol. 2010 Apr;34 Suppl 2:69-72.</citation>
    <PMID>21305727</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 20, 2021</study_first_submitted>
  <study_first_submitted_qc>March 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 20, 2021</last_update_submitted>
  <last_update_submitted_qc>March 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hayatabad Medical Complex</investigator_affiliation>
    <investigator_full_name>Yousaf Jamal Mahsood</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Central retinal vein occlusion; bevacizumab; triamcinolone; intravitreal; macular edema.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 30, 2021</submitted>
    <returned>June 22, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

